Forbion related stories
All articles and analysis
A big LP you need to knowYup Kim, CIO of Texas Municipal Retirement System, is a fan of venture capital and says the $44bn public pension may invest 'several hundreds of millions' per year in the asset class.
Yup Kim’s bold vision for Texas Municipal Retirement SystemThe new CIO of the $44bn public pension system is pushing hard into PE, and VC is a big part of his plan.
DOWNLOAD: VC fundraising hits six-year lowVenture capital funds closed on $104.7bn worldwide in 2024, or 18% less than they raised in 2023, according to our annual Global Venture Capital Fundraising Report.
Swiss biotech firm grabs $147m Series BThe investors include EQT Life Sciences, Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.
Life sciences investor Forbion raises more than €2.2bn across two fundsForbion Growth Opportunities III raised €1.2 billion and Forbion Ventures VII raised €890 million.
Forbion is raising new fund to address 'planetary health challenges'Forbion, a life sciences venture capital firm, has held a first close on €75m for Forbion BioEconomy Fund I, which is targeting €150m.
Three big LPs are warming to growth equityAlaska Permanent, CalPERS and New Mexico SIC are more interested in growth equity since valuations have come down for growth-stage companies.
CalPERS is already putting more money into VC and growthCalPERS committed a combined $2.1 billion to 13 growth equity and VC funds in the third quarter of 2023, a new report shows.
How institutions are bridging Europe’s scale-up gapEuropean venture funds and founders have had their own fundraising challenges.
- Biotech company enGene to go public in Forbion-sponsored SPAC merger
Upon closing of the deal, the combined company will be named enGene Holdings, whose common shares are expected to be listed on the Nasdaq.